The global hepatitis therapeutics market size is expected to reach USD 20.84 billion by 2030, registering a CAGR of 3.7% during the forecast period, according to a new report by Grand View Research, Inc. Few factors that are expected to drive the market over the forecast period include the rising number of hepatitis infected population, growing consumption of alcohol & drugs, and improving accessibility to hepatitis drugs.

 

Based on the duration for which the patient suffers, viral hepatitis is generally categorized into two types. If the condition lasts for less than six months, then it is classified as acute, when the condition persists for more than six months, then it is a case of chronic hepatitis. People with HIV infection & HCV-infected sexual partners, recipients of infected blood, patients who inject drugs & use intranasal drugs, and population groups who live in unhygienic conditions are at high risk of hepatitis.

 

Access the Hepatitis Therapeutics Market Size, Share & Trends Analysis Report By Disease (Hepatitis A, Hepatitis B, Hepatitis C), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2024 - 2030

 

Based on the estimates of WHO, approximately 400 million people are infected with at least one form of hepatitis globally, and annually nearly 1.4 people die due to the condition. In order to prevent hepatitis, few government and private agencies are actively involved in the vaccination drive to prevent hepatitis. As compared to hepatitis A and B, HCV leads to more serious complications. According to the estimates of WHO, globally annually 150 million are impacted by hepatitis C infection. Moreover, the majority of HCV infected patients develop liver cancer or liver cirrhosis and nearly 700,000 people die due to hepatitis C infection & associated conditions.

 

 

Hepatitis Therapeutics Market Report Highlights

·        Owing to the high prevalence of target disease with subsequently surge in treatment rate HCV, thus hepatitis C therapeutics held the majority market share in 2023

 

·        In 2023, North American region accounted for the majority of the revenue share, owing to high patient awareness levels and the presence of advanced healthcare infrastructure

 

·        However, Asia Pacific is anticipated to witness the maximum growth with a CAGR of 6.6% over the forecast period owing to rapidly increasing healthcare expenditure.

 

 

Key Hepatitis Therapeutics Company Insights

Some of the key companies operating in the hepatitis therapeutics market include Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Zydus Group, GSK plc, AbbVie Inc., Gilead Sciences, Inc., Merck & Co., Inc., Lupin, and Cipla. Vendors in the market are focusing on increasing customer base to gain a competitive edge in the industry. Therefore, key players are taking several strategic initiatives, such as mergers and acquisitions, and partnerships with other major companies.

 

Order your free sample copy of “Hepatitis Therapeutics Market Report 2024 - 2030, published by Grand View Research

 

 

Key Hepatitis Therapeutics Companies:

The following are the leading companies in the hepatitis therapeutics market. These companies collectively hold the largest market share and dictate industry trends.

 

·        Teva Pharmaceutical Industries Ltd.

·        Bristol-Myers Squibb Company

·        F. Hoffmann-La Roche Ltd

·        Zydus Group

·        GSK plc.

·        AbbVie Inc.

·        Gilead Sciences, Inc.

·        Merck & Co., Inc.

·        Lupin

·        Cipla

 

 

Recent Developments

 

·        In February 2024, the U.S. Food and Drug Administration (FDA) prioritized GSK plc's bepirovirsen for development as a treatment for chronic hepatitis B. This drug is undergoing phase 3 clinical trials to confirm its effectiveness.

 

·        In October 2023, Rostec was expected to launch Antigen-Neo, Russia's first intravenous specific immunoglobulin for hepatitis B prevention in children and adults. It was approved for preventing hepatitis B and is also effective for cases transmitted from hepatitis B surface antigen-positive pregnant women.

 

About Grand View Research:

Grand View Research, Inc. is a market research and consulting company that provides off-the-shelf, customized research reports and consulting services. To help clients make informed business decisions, we offer market intelligence studies, ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials, and energy. With a deep-seated understanding of varied business environments, Grand View Research provides strategic objective insights. For more information, visit www.grandviewresearch.com

 

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058
Email:  sales@grandviewresearch.com